ReviewHepatology communications2025
The pathophysiological role of portal hypertension in metabolic dysfunction-associated steatotic liver disease.
Review in Hepatology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portal hypertension (PH) develops when static lesions such as steatosis, fibrosis, and cirrhotic nodules accumulate within the liver due to alcohol, metabolic syndrome, or other etiologies. In addition, dynamic components further enhance the hepatic vascular resistance (HVR) caused by activated hepatic stellate cells (HSCs) and sinusoidal endothelial cells (SECs). Both alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD) are significant global health burdens, and knowledge on the pathophysiology behind the development of complications to PH is crucial. Hepatic cells with compromised function, such as hepatocytes, HSCs, and SECs, are deeply involved in the hemodynamic changes, impaired degradation of vasoactive substances, production of vasodilators, immune function, and mechanosensing. PH remains the main driver of liver-related complications, but it is often measured lower than expected in MASLD, partly because of the presence of inter-sinusoidal communications. The aim of this overview is to highlight pathophysiological aspects of PH in ALD and MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.